Literature DB >> 6690339

Plasma norepinephrine and epinephrine levels in essential hypertension.

D S Goldstein, C R Lake.   

Abstract

Almost all comparative studies of plasma catecholamines in patients with essential hypertension (EH) and in normotensive controls have reported higher mean norepinephrine (NE) or epinephrine (E) levels in the hypertensive patients, but only about 40% of the studies have been positive, i.e., have reported statistically significant hypertensive-normotensive (H-N) differences. Virtually all studies of NE in young, consistently hypertensive patients were positive, as well as all studies of E in relatively tachycardic patients. Plasma NE increased with age in normotensive control but not EH groups. The likelihood that a study was positive with respect to NE was independent of the likelihood with respect to E. In 189 individuals with EH and 130 normotensive controls, NE increased with age in controls but not in patients with EH, so that the extent of the H-N difference in NE varied inversely with patient age. Among 41 other individuals with EH and 59 other normotensive controls, the distributions of NE and E values were shifted upward in EH. NE and E values were uncorrelated. Plasma NE levels are abnormally high in some patients with EH--especially those who are young and consistently hypertensive--and E levels are independent of age and NE. Increased sympathetic nervous system and/or sympathoadrenomedullary activity characterize a proportion of patients with EH.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6690339

Source DB:  PubMed          Journal:  Fed Proc        ISSN: 0014-9446


  2 in total

1.  Pioneer Award Address: ignorance isn't biased: comments on receiving the Pioneer Award.

Authors:  David S Goldstein
Journal:  Cleve Clin J Med       Date:  2009-04       Impact factor: 2.321

Review 2.  Is Mania the Hypertension of the Mood? Discussion of A Hypothesis.

Authors:  Zoltán Rihmer; Xénia Gonda; Péter Döme
Journal:  Curr Neuropharmacol       Date:  2017-04       Impact factor: 7.363

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.